Moving Medicine Forward

PureTech is led by a proven and seasoned management team. Collectively, they have overseen the research and development of products supporting 20 regulatory approvals and has been involved in the C-suite of companies acquired for more than $13 billion cumulatively.

Joep Muijrers, PhD
Chief of Portfolio Strategy
Miscellaneous Information:

Joep Muijrers, PhD, is the chief of portfolio strategy at PureTech. Dr Muijrers has two decades of experience in corporate and capital finance, specifically focused on investment, M&A, portfolio management, strategic asset allocation, financial and regulatory reporting and fundraising. Prior to joining PureTech, he was a portfolio manager and partner at LSP (Life Sciences Partners), a specialist investor group with sole focus on investing in healthcare and life sciences, in the Netherlands and in Boston. At LSP, Dr Muijrers was responsible for investing in publicly traded companies, a strategy that generated a total return in excess of 900 percent, more than twice the return of the Nasdaq Biotechnology Index during the same period (Q2 2008 – Q1 2018). Notable investments included companies that were acquired by large pharma (Ablynx, CoLucid, InterMune, Kite Pharma, NeuroDerm) and/or became leaders in their respective areas of activity (Evotec, Genmab, GW Pharmaceuticals, MorphoSys, Neurocrine). Prior to joining LSP, he held the position of director corporate finance and capital markets at Fortis Bank, currently part of ABN AMRO. Dr Muijrers is currently a member of the board of directors of Alivio Therapeutics, Inc., Entrega, Inc., Follica, Incorporated and Sonde Health, Inc. Dr Muijrers holds a PhD degree in molecular biology from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and an MS in biochemistry from the University of Nijmegen, the Netherlands.

Share our vision, creativity & dedication - Join PureTech Health

Share our vision, creativity & dedication.

Join PureTech